ArticleCancer management and research2020
Exosomal miR-499a-5p Inhibits Endometrial Cancer Growth and Metastasis via Targeting VAV3.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Pooled it
- Exosomal-miR-32-5p directly targets FOXN2 to regulate the proliferation, migration and apoptosis of uterine corpus endometrial carcinoma via the PI3K/AKT/BCL-2 pathway.Oncology letters · 2026Article
- Review
- Machine learning-based prediction of drug response in ischemia reperfusion animal model.Scientific reports · 2025Article
- The role of extracellular vesicles in the communication between endometrial cancer cells and tumour-associated macrophages: a review.Journal of cancer research and clinical oncology · 2025Review
- Exosomal non-coding RNAs: mediators of crosstalk between cancer and cancer stem cells.Cell death discovery · 2025Review
- Transplantation of miR-216a-5p-overexpressing mesenchymal stem cells encapsulated in a thermosensitive hydrogel promotes functional recovery in a rat model of spinal cord injury.European journal of medical research · 2025Article
- Muscle-specific miR-499-5p delivered by small extracellular vesicles impairs endothelial function and ischemic hindlimb recovery in diabetic mice.Cardiovascular diabetology · 2025Article
- Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs.Cancer cell international · 2025Review
- Mesenchymal stem cell exosome therapy: current research status in the treatment of neurodegenerative diseases and the possibility of reversing normal brain aging.Stem cell research & therapy · 2025Review
- Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management - a comprehensive review.Cancer chemotherapy and pharmacology · 2025Review
- MiR-499a-5p Promotes the Proliferation and Migration of Uterine Leiomyoma Cells by Activating the Wnt/β-Catenin Signaling Pathway.International journal of women's health · 2025Article
- Emerging drug delivery approach using nanomaterials for the treatment of endometrial cancer.Frontiers in medical technology · 2025Review
- From biomolecules to breakthroughs: exosomes as next-generation theranostics in female infertility.Frontiers in cell and developmental biology · 2025Review
- Molecular mechanism of aerobic exercise in miRNAs and the anti-tumoral effects.Frontiers in oncology · 2025Review
- Ferroptosis contributes to the progression of female-specific neoplasms, from breast cancer to gynecological malignancies in a manner regulated by non-coding RNAs: Mechanistic implications.Non-coding RNA research · 2024Review
- Article
- Review
- Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe current therapeutic strategies for endometrial cancer are limited and unsatisfactory. Accumulating evidence suggest that microRNAs (miRNAs) participate in tumor growth and metastasis. Mesenchymal stem cells (MSCs) derived exosomes (Exos) are considered as better miRNA delivery vehicles. Here, we investigated the therapeutic effect of exosomal miR-499a-5p (miR-499) in human endometrial cancer metastasis.
methodsMicroarray analysis and RT-PCR were performed to detect the relative expression of miR-499 in endometrial cancer tissues and cell lines. MSC-derived Exos were characterized by transmission electron microscope (TEM), Western blot (WB), and nanoparticle tracking analysis (NTA). miR-499 was loading into Exos using electroporation. Cell proliferation and angiogenesis capacity were tested by 5-ethynyl-29-deoxyuridine (EdU) assay and tube formation assay, respectively. Dual-luciferase reporter assay (DLR) was used to confirm the connection of miR-499 and VAV3.
resultsWe found that the expression of miR-499 was significantly downregulated in cancer tissues compared with adjacent tissues in endometrial cancer patients. Moreover, exosomal miR-499 not only dramatically suppressed endometrial cancer cells proliferation, endothelial cells tube formation in vitro, but also inhibited tumor growth and angiogenesis in vivo. In addition, we confirmed that miR-499 directly targets the 3'UTR sequence of VAV3.
conclusionThe novel identified exosomal miR-499 functions as a tumor suppressor in endometrial cancer though regulating VAV3, and these findings could be a valid molecular target for endometrial cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.